| 161.42 2.15 (1.35%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 218.8  |
1-year : | 239.7 |
| Resists | First : | 187.33 |
Second : | 205.22 |
| Pivot price | 171.17 |
|||
| Supports | First : | 158.38 |
Second : | 131.78 |
| MAs | MA(5) : | 163.11 |
MA(20) : | 171.94 |
| MA(100) : | 171.02 |
MA(250) : | 119.83 |
|
| MACD | MACD : | -6.9 |
Signal : | -5.7 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 8.3 |
| RSI | RSI(14): 33.9 |
|||
| 52-week | High : | 212.75 | Low : | 60.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INSM ] has closed above bottom band by 10.3%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 164.31 - 165.4 | 165.4 - 166.38 |
| Low: | 155.72 - 157.1 | 157.1 - 158.34 |
| Close: | 159.29 - 161.46 | 161.46 - 163.43 |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Mon, 19 Jan 2026
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
Thu, 15 Jan 2026
Looking At Insmed's Recent Unusual Options Activity - Benzinga
Tue, 13 Jan 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM - Chartmill
Mon, 12 Jan 2026
Assessing Insmed (INSM) Valuation After Strong Multi‑Year Returns And Recent Share Price Pullback - Sahm
Fri, 09 Jan 2026
Insmed posts early 2025 revenue beating consensus (INSM:NASDAQ) - Seeking Alpha
Fri, 09 Jan 2026
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 213 (M) |
| Shares Float | 191 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 101.5 (%) |
| Shares Short | 8,930 (K) |
| Shares Short P.Month | 8,930 (K) |
| EPS | -6.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.44 |
| Profit Margin | -264.9 % |
| Operating Margin | -183.7 % |
| Return on Assets (ttm) | -28.1 % |
| Return on Equity (ttm) | -165.7 % |
| Qtrly Rev. Growth | 52.4 % |
| Gross Profit (p.s.) | 1.6 |
| Sales Per Share | 2.09 |
| EBITDA (p.s.) | -4.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -883 (M) |
| Levered Free Cash Flow | -440 (M) |
| PE Ratio | -26.12 |
| PEG Ratio | 0 |
| Price to Book value | 36.27 |
| Price to Sales | 77.01 |
| Price to Cash Flow | -38.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|